newsfilter
← Latest News
GlobeNewswire·

Eliem Therapeutics Provides Program Updates and an Overview of Expected Near-Term Milestones

ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) is fully enrolled Investigational New Drug (IND) application planned in Q1 2022 for ETX-155 Phase 2 trials in major depressive disorder (MDD) and perimenopausal depression (PMD)